Archives
ACE2 Peptidase Activity and Angiotensin (1-7)
ACE2 Peptidase Activity and Angiotensin (1-7)
Angiotensin-converting enzyme 2 (ACE2) occupies a central position in renin–angiotensin system biology because it converts the vasoconstrictor angiotensin II into the vasodilatory peptide Angiotensin (1-7). The study by Saulnier and colleagues, published in Archives of Biochemistry and Biophysics, examines the structural features that determine whether angiotensin peptides compete with an artificial ACE2 substrate. Rather than treating angiotensin fragments as interchangeable ligands, the work asks how N-terminal and C-terminal sequence changes alter recognition by ACE2.
Study Background and Research Question
Angiotensin I is a decapeptide generated from angiotensinogen by renin. ACE1 removes a C-terminal dipeptide to produce Angiotensin II, whose sequence is Asp-Arg-Val-Tyr-Ile-His-Pro-Phe. ACE2 then removes the terminal phenylalanine from Angiotensin II, generating the seven-residue peptide Angiotensin (1-7), with the sequence Asp-Arg-Val-Tyr-Ile-His-Pro. This conversion is physiologically important because it shifts signaling away from several actions associated with Angiotensin II, including vasoconstriction and tissue-remodeling responses. The biochemical framework is described in the reference study.
The investigators focused on a specific unresolved question: does ACE2 recognize angiotensin peptides mainly through their C-terminal phenylalanine, their N-terminal residues, overall peptide length, or a combination of these features? This distinction matters when interpreting ACE2 activity assays and when predicting which endogenous angiotensin fragments may be substrates, competitors, or modulators of the enzyme.
Key Innovation from the Reference Study
The principal innovation was a comparative substrate-recognition strategy. The authors tested a panel of naturally related angiotensin molecules rather than examining Angiotensin II alone. The panel included peptides with selective removal of C-terminal or N-terminal residues, allowing the effects of individual sequence segments to be considered in a common assay format.
This design revealed that ACE2 recognition is not governed by a simple rule in which shorter peptides are always poorer substrates. Removal of the C-terminal Phe abolished detectable competition by several peptides, whereas removal of the N-terminal Asp initially enhanced competition in the case of Angiotensin III. Removing two N-terminal residues produced a different result. The study therefore provides a more nuanced view of ACE2 substrate recognition, with both termini contributing in a context-dependent manner.
Methods and Experimental Design Insights
ACE2 activity was measured with the Fluorimetric SensoLyte 390 ACE2 Activity Assay. This platform uses an Mca/Dnp fluorescence-resonance-energy-transfer peptide. Cleavage of the labeled artificial substrate changes the fluorescence signal, so the natural angiotensin peptides can be evaluated by adding them as potential competitors. Reduced fluorescence indicates that a test peptide interferes with cleavage of the fluorogenic substrate, whereas increased signal suggests potentiation of the measured ACE2 activity.
The peptide panel included Angiotensin I, Angiotensin II, Angiotensin III, Angiotensin IV, Angiotensin (1-9), Angiotensin (1-7), Angiotensin (2-7), Angiotensin (5-7), Angiotensin (5-8), Angiotensin (1-5), and Angiotensin (1-4). This arrangement was useful because it separated several variables: retention or loss of the C-terminal Phe, progressive N-terminal trimming, and shortening of the peptide beyond the canonical ACE2 product.
Protocol Parameters
- Assay format: Use a fluorogenic Mca/Dnp FRET substrate to monitor ACE2 peptidase activity through changes in fluorescence.
- Competition design: Compare angiotensin peptides that differ in defined N-terminal or C-terminal residues within the same activity-assay framework.
- Primary readout: Interpret reduced fluorescence as competition with the artificial substrate and enhanced fluorescence as potentiation of the assay signal.
- Evidence boundary: Treat competition as a substrate-recognition indicator, not as a direct measurement of individual kcat, Km, or physiological turnover rates.
For researchers adapting this approach, the matched peptide panel is as important as the fluorescence readout. Testing only Angiotensin II and Angiotensin (1-7) would not reveal the non-linear effects of N-terminal trimming observed in the study.
Core Findings and Why They Matter
Angiotensin II competed effectively with the artificial fluorogenic substrate, consistent with its established role as an ACE2 substrate. Angiotensin III, which lacks the N-terminal Asp but retains the C-terminal Phe, showed an even stronger ability to compete. These results led the authors to identify Angiotensin II and Angiotensin III as the best natural substrates among the molecules tested.
The C-terminal findings were particularly informative. Removing Phe from Angiotensin II eliminated the ability of Angiotensin (1-7), Angiotensin (2-7), and Angiotensin (5-7) to compete effectively. This pattern supports an important recognition contribution from the C-terminal phenylalanine. It also clarifies why Angiotensin (1-7), despite being generated by ACE2, should not automatically be expected to behave like an equally strong substrate or competitor in an ACE2 activity assay.
N-terminal changes produced a more complex pattern. Loss of the first Asp enhanced competition by Angiotensin III, but removal of both Asp and Arg reduced competition by Angiotensin IV and Angiotensin (5-8). The effect is therefore not a simple improvement caused by progressive shortening. Instead, ACE2 appears to respond to a particular combination of terminal residues and peptide length.
Angiotensin I and Angiotensin (1-9) did not strongly compete under the tested conditions. Unexpectedly, the shorter Angiotensin (1-5) and Angiotensin (1-4) peptides potentiated the measured ACE2 activity. This observation should not be interpreted automatically as evidence that these fragments are physiologically important ACE2 substrates. It does, however, show that short angiotensin peptides can alter an enzymatic assay in ways that are not captured by a substrate-versus-nonsubstrate classification.
Overall, the study shifts attention from peptide naming conventions to sequence-dependent enzyme recognition. It also provides a practical warning: an assay signal obtained with a fluorogenic substrate may reflect competition or modulation by endogenous peptide fragments, not only the intrinsic activity of ACE2.
Comparison with Existing Internal Articles
The reference study examines purified biochemical recognition by ACE2, whereas the internal article Periodontopathogen Proteases Redirect RAS to Generate Angiotensin (1-7) considers a different source of local peptide production. That article describes surface-associated proteases from Porphyromonas gingivalis and Tannerella forsythia as contributors to Angiotensin (1-7) generation. Together, the studies distinguish host ACE2-mediated conversion from microbial proteolysis and show why the origin of a measured Angiotensin (1-7) signal must be considered in tissue or microbiome experiments.
The internal resource Angiotensin (1-7): Applied Protocols and Advanced Use-Cases is more focused on experimental deployment of the peptide and downstream assay planning. Its relationship to the reference paper is complementary: Saulnier et al. define upstream ACE2 substrate behavior, while the protocol-oriented article addresses how investigators may study the biological consequences of the ACE2 product. Neither resource should be used to substitute for direct kinetic characterization when precise catalytic parameters are required.
Limitations and Transferability
The main limitation is that the study uses competition with an artificial fluorogenic substrate as its principal readout. A strong competitor may be a favorable substrate, but the assay does not by itself establish the complete catalytic sequence, cleavage rate, product release rate, or physiological concentration range for each peptide. The potentiation produced by Angiotensin (1-5) and Angiotensin (1-4) especially requires follow-up experiments using direct product analysis and purified kinetic measurements.
Sequence deletions also change more than molecular length. They can alter charge distribution, conformational flexibility, and interactions with the enzyme’s binding pockets. Consequently, the results are highly informative for comparative recognition but should not be generalized to every angiotensin-like peptide or to intact tissues without additional validation. Cell-surface ACE2, competing peptidases, peptide degradation, receptor binding, and local compartmentalization could all change the relative abundance of these fragments in vivo.
The findings are most transferable to assay design, interpretation of ACE2 substrate panels, and mechanistic studies of how terminal residues shape peptidase recognition. They are less directly transferable to predictions about blood pressure, fibrosis, inflammation, or receptor-mediated signaling because those biological outcomes were not measured in this experiment.
Why this cross-domain matters, maturity, and limitations
ACE2 also gained attention as a cellular receptor for SARS-CoV-2, a role noted in the reference paper. The enzymology studied here and viral entry are related through the same protein but represent distinct functional questions. These experiments do not measure spike-protein binding, membrane entry, infection, or antiviral efficacy. Thus, the work supports careful separation of ACE2 peptidase mechanisms from claims about respiratory viral biology.
Research Support Resources
For follow-up experiments using the ACE2-generated peptide, researchers can use Angiotensin (1-7) (SKU A1041) in workflows examining this endogenous heptapeptide hormone and Mas receptor agonist. Relevant downstream contexts include PI3K/AKT signaling modulation, ERK pathway regulation, evaluation of its role as an anti-fibrotic and anti-inflammatory agent, and cerebroprotection in ischemic stroke. The product information reports purity above 99.7% by HPLC and mass spectrometry and high solubility in water; researchers should review the handling and storage guidance before preparing solutions.